Sodium-dependent glucose cotransporter inhibitors

Pectolinaligenin and its glycosides are developed as effective SGLT inhibitors, addressing the inadequacy of existing inhibitors by safely inhibiting SGLT, suitable for both food and pharmaceutical applications.

JP7582612B2Active Publication Date: 2024-11-13DAICEL CORP +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2020184285
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-11-04
Publication Date
2024-11-13
Estimated Expiration
2040-11-04

AI Technical Summary

Technical Problem

Existing SGLT inhibitors, including synthetic compounds and chlorogenic acid, do not provide sufficient inhibitory activity against sodium-dependent glucose cotransporters, necessitating the development of a more effective and naturally occurring SGLT inhibitor.

Method used

Pectolinaligenin and/or its glycosides are identified as active ingredients with excellent SGLT inhibitory activity, offering a new class of SGLT inhibitors.

Benefits of technology

Pectolinaligenin and its glycosides effectively inhibit SGLT, providing a safe and versatile solution for preventing or treating hyperglycemia-related conditions, suitable for use in food and pharmaceutical products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582612000001
    Figure 0007582612000001
  • Figure 0007582612000002
    Figure 0007582612000002
  • Figure 0007582612000003
    Figure 0007582612000003
Patent Text Reader

Abstract

To identify a component having excellent sodium-dependent glucose cotransporter inhibitory activity and provide a new SGLT inhibitor.SOLUTION: A sodium-dependent glucose cotransporter inhibitor contains pectolinarigenin and / or glycoside thereof as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to sodium-dependent glucose cotransporter (SGLT) inhibitors. [Background technology]

[0002] In recent years, the number of diabetes patients has been steadily increasing due to the Westernization of diet, high calorie intake, lack of exercise caused by the development of a car-oriented society, and aging. Diabetes is a systemic metabolic disorder that causes chronic hyperglycemia due to insufficient insulin action in the body caused by reduced insulin sensitivity in the liver, fat, and muscles, and reduced insulin secretion ability in the pancreas, and is known to promote the onset and progression of cardiovascular diseases such as stroke and ischemic heart disease. Diabetes not only reduces quality of life, but also places a huge burden on society in terms of medical economy, making it a social problem.

[0003] On the other hand, as sugar transporters that take up glucose into the body, SGLT, which actively transports glucose depending on the sodium concentration, and glucose transporter (GLUT), which passively transports glucose, have been identified. Among these sugar transporters, SGLT has been identified as having subtypes SGLT1, SGLT2, and SGLT3. For example, SGLT1 is expressed in the small intestine and kidney, and is known to absorb glucose derived from food in the small intestine and reabsorb glucose from urine in the kidney. In recent years, attempts have been made to prevent or treat diabetes by inhibiting or delaying glucose absorption using SGLT inhibitors to suppress the rise in blood glucose level (see, for example, Patent Documents 1 to 3). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2019-182852 A [Patent Document 2] JP 2012-62308 A [Patent Document 3] JP 2011-32174 A Summary of the Invention [Problem to be solved by the invention]

[0005] Diabetic patients need to take SGLT inhibitors, including SGLT1, for a long time, so it would be desirable to be able to easily ingest SGLT inhibitors using naturally occurring ingredients in the form of food, etc. However, most of the SGLT inhibitors reported so far are synthetic compounds that do not exist in nature. In addition, although chlorogenic acid, a naturally occurring ingredient, is known to have SGLT inhibitory activity, its SGLT inhibitory activity is not sufficient.

[0006] Therefore, an objective of the present disclosure is to identify a component having excellent SGLT inhibitory activity and to provide a new SGLT inhibitor. [Means for solving the problem]

[0007] The present inventors have conducted intensive research to solve the above problems and have found that pectolinarigenin and / or its glycosides have excellent SGLT inhibitory activity and can be used as an active ingredient of an SGLT inhibitor. The invention described in the present disclosure was completed through further investigation based on such findings.

[0008] The present disclosure provides SGLT inhibitors according to the embodiments set out below. Item 1. An SGLT inhibitor containing pectinarigenin and / or its glycoside as an active ingredient. Item 2. The SGLT inhibitor according to Item 1, which is used for inhibiting SGLT. Item 3. The SGLT inhibitor according to Item 1 or 2, for use in the prevention or treatment of diabetes mellitus. Item 4. The SGLT inhibitor according to any one of Items 1 to 3, which is a food or drink for inhibiting a sodium-dependent glucose cotransporter. Item 5. The SGLT inhibitor according to any one of Items 1 to 3, which is a pharmaceutical for inhibiting a sodium-dependent glucose cotransporter. Effect of the Invention

[0009] According to the SGLT inhibitor of the present disclosure, by using pectinarigenin and / or its glycoside as an active ingredient, SGLT can be effectively inhibited, and it becomes possible to prevent or treat diseases and symptoms caused in part by hyperglycemia such as diabetes. In addition, since pectinarigenin and its glycoside are naturally occurring ingredients, the SGLT inhibitor of the present disclosure is highly safe and can be used in various products such as food and beverages and pharmaceuticals. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 shows the results of evaluating the effects of pectinarigenin and chlorogenic acid on SGLT1 activity in Test Example 1. [Diagram 2] FIG. 1 shows the results of evaluating the relationship between pectinarigenin concentration and SGLT1 inhibitory activity in Test Example 2. [Diagram 3] FIG. 1 shows the results of evaluating the effects of pectolinarigenin and pectolinarin on SGLT1 activity in Test Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] One embodiment of the present disclosure is an SGLT inhibitor containing pectinarigenin and / or its glycoside as an active ingredient. The SGLT inhibitor according to one embodiment of the present disclosure will be described in detail below.

[0012] [Active ingredients] The SGLT inhibitors of the present disclosure use pectinarigenin and / or its glycosides as active ingredients.

[0013] Pectolinarigenin, also known as 5,7-dihydroxy-4',6-dimethoxyflavone (IUPAC name), is a flavonoid and is the aglycone of pectolinarin.

[0014] A glycoside of pectolinarigenin is a compound in which a sugar is glycosidically bonded to pectolinarigenin. An example of a glycoside of pectolinarigenin used in the SGLT inhibitor of the present disclosure is a compound in which a sugar is glycosidically bonded to the hydroxyl group of the A ring of pectolinarigenin. In the glycoside of pectolinarigenin, the type of sugar bound is not particularly limited, and examples thereof include monosaccharides such as glucose, mannose, galactose, rhamnose, xylose, arabinose, apiose, etc.; disaccharides consisting of one or two of these monosaccharides; trisaccharides consisting of one or more of these monosaccharides; tetrasaccharides consisting of one or more of these monosaccharides; and pentasaccharides consisting of one or more of these monosaccharides. In one embodiment of the SGLT inhibitor of the present disclosure, a suitable example of a glycoside of pectolinarigenin is pectolinarin.

[0015] In the SGLT inhibitor of the present disclosure, one compound selected from pectinarigenin and its glycosides may be used as the active ingredient, or two or more compounds may be used in combination. In one embodiment of the SGLT inhibitor of the present disclosure, the active ingredient used is preferably pectinarigenin and / or pectolinarin, more preferably pectinarigenin.

[0016] The origin of pectolinarigenin and / or its glycosides used in the SGLT inhibitors of the present disclosure is not particularly limited, and they may be obtained from plants, or may be obtained by chemical synthesis, enzymatic synthesis, or the like.

[0017] From the viewpoints of safety, reduction of production costs, etc., in one embodiment of the SGLT inhibitor of the present disclosure, pectinarigenin and / or its glycoside derived from a plant can be used. Examples of plants from which pectinarigenin is derived include plants of the genus Cirsium in the family Asteraceae, specifically Cirsium brevicaule, Cirsium boninense, Cirsium spinosum, Cirsium maritimum, Cirsium irimtiense, and Cirsium yakushimense. Among these plants from which pectinarigenin and / or its glycoside are derived, Cirsium brevicaule is a preferred embodiment.

[0018] Furthermore, in one embodiment of the SGLT inhibitor of the present disclosure, pectinarigenin and / or its glycosides may be purified, or may be a crude product, or may be in the form of a plant extract containing pectinarigenin and / or its glycosides, or may be a product obtained by simply subjecting a plant containing pectinarigenin and / or its glycosides to treatment such as steaming, drying, roasting, shredding, or crushing.

[0019] A plant extract containing pectinarigenin and / or its glycosides can be obtained, for example, by subjecting the above-mentioned plant of the genus Cirsium of the Asteraceae family to an extraction treatment.

[0020] Examples of parts of Cirsium genus plants of the Asteraceae family that can be used for extraction include leaves, stems, roots, rhizomes, fruits, seeds, seed coats, flowers, etc., and in a preferred embodiment, leaves are used. If necessary, the parts of Cirsium genus plants of the Asteraceae family that can be extracted may be subjected to pretreatment such as steaming, drying, roasting, shredding, or crushing.

[0021] The extraction treatment may be any common extraction method used in the production of plant extracts, such as solvent extraction treatment, supercritical extraction treatment, steam distillation treatment, etc. Among these, a preferred embodiment is solvent extraction treatment.

[0022] The extraction solvent used in the solvent extraction treatment is not particularly limited as long as it is a solvent capable of extracting pectolinarigenin and / or its glycoside, and examples thereof include water; alcohols such as methanol, ethanol, propanol, butanol, and the like; polyhydric alcohols such as ethylene glycol, propylene glycol, butylene glycol, glycerin, and the like; ketones such as acetone, methyl ethyl ketone, and the like; esters such as methyl acetate, ethyl acetate, and the like; ethers such as tetrahydrofuran, diethyl ether, and the like; halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform, and the like; aliphatic hydrocarbons such as hexane, pentane, and the like; aromatic hydrocarbons such as toluene, and the like; polyethers such as polyethylene glycol, and organic solvents such as pyridines, and mixtures of these organic solvents and water. These extraction solvents may be used alone or in combination of two or more. Among these extraction solvents, a preferred embodiment is ethanol, or a mixture of ethanol and water.

[0023] The solvent extraction process may be carried out by immersing or refluxing the part to be extracted in the extraction solvent, and a person skilled in the art can appropriately determine the amount of extraction solvent used, the temperature during the extraction process, the extraction process time, etc.

[0024] By removing the residue after the solvent extraction treatment, a plant extract containing pectolinarigenin and / or its glycosides can be obtained. The removal of the residue can be carried out, for example, by suction filtration, a filter press, a cylinder press, a decanter, a centrifuge, a filtration centrifuge, or the like.

[0025] The obtained extract may be subjected to further concentration, washing and purification treatments such as concentration, drying, washing with water, washing with organic solvents, desalting, activated carbon treatment, recrystallization, distribution purification, column chromatography, vacuum distillation, etc., to remove impurities, if necessary. These treatments may be performed by repeating the same treatment multiple times, or by combining two or more different treatments. Furthermore, the obtained extract may be further subjected to treatments such as powdering, granulation, emulsification, etc., to adjust it into a desired form.

[0026] The content of pectinarigenin and / or its glycoside in the SGLT inhibitor of the present disclosure is not particularly limited, as long as it is an effective amount that can inhibit SGLT in the body, and can be set appropriately depending on the application, dosage form, administration form, etc.

[0027] [Other added ingredients] In one embodiment of the SGLT inhibitor of the present disclosure, in addition to pectinarigenin and / or its glycoside, other additive components may be contained depending on the dosage form, formulation, etc. The type and content of the additive components are appropriately set depending on the dosage form, formulation, etc.

[0028] [Dosage form / formulation] The dosage form of the SGLT inhibitor of the present disclosure is not particularly limited and may be any of solid, semi-solid, or liquid, and may be appropriately selected depending on the formulation form, administration method, etc. of the SGLT inhibitor.

[0029] The method of application of the SGLT inhibitor of the present disclosure is not particularly limited, and may be any of oral ingestion, oral administration, intravascular (intra-arterial or intravenous) administration, transdermal administration, enteral administration, pulmonary administration, intranasal administration, etc., but a preferred embodiment includes oral ingestion or oral administration.

[0030] The formulation of the SGLT inhibitor of the present disclosure may be in the form of a food or drink, or a pharmaceutical.

[0031] When the SGLT inhibitor of the present disclosure is formulated into a food or beverage, the active ingredient may be combined with other food materials or additives to prepare a desired form. Examples of such food or beverage include general food or beverage, specific health foods, nutritional functional foods, and functional foods. The form of these food or beverage is not particularly limited, but specific examples include capsules (soft capsules, hard capsules), tablets, granules, powders, jellies, liposome preparations, and other supplements; beverages such as nutritional drinks, fruit juice drinks, carbonated drinks, and lactic acid drinks; and luxury items such as dumplings, ice cream, sherbet, gummy candy, and candy. Among these food or beverage, supplements and beverages are preferred.

[0032] When the SGLT inhibitor of the present disclosure is formulated into a pharmaceutical formulation, the active ingredient may be prepared into a desired form as is, in combination with other additive ingredients, or in combination with a delivery technique according to the dosage form. Specific examples of such pharmaceuticals include oral medicines such as drinks, capsules (soft capsules, hard capsules), tablets, granules, powders, jellies, and syrups; liposome preparations, injections, enteral preparations, drips, nasal drops, injections, infusions, suppositories, and the like. Among these pharmaceuticals, oral medicines are preferred.

[0033] When the SGLT inhibitor of the present disclosure is in the form of a food or beverage, or an oral drug, the content of the active ingredient pectolinarigenin and / or its glycoside is not particularly limited, as long as it is an effective amount that can inhibit SGLT in the body, and may be set appropriately depending on the dosage form and formulation, and is, for example, 0.01 to 100% by mass, preferably 0.1 to 50% by mass, and more preferably 1 to 30% by mass.

[0034] [Application] The SGLT inhibitor of the present disclosure is used for inhibiting SGLT in vivo. The SGLT subtypes to be inhibited by the SGLT inhibitor of the present disclosure may be any of SGLT1, SGLT2, and SGLT3, preferably SGLT1 and SGLT2, more preferably SGLT1.

[0035] For example, since inhibition of SGLT1 can inhibit or delay glucose absorption in the body, in one embodiment of the SGLT inhibitor disclosed herein, the use of SGLT1 inhibition can be used to prevent or treat diseases or symptoms caused in part by hyperglycemia.

[0036] Examples of diseases and symptoms caused in part by hyperglycemia include diabetes (including both types 1 and 2), impaired glucose tolerance, impaired fasting glucose, diabetic complications (e.g., diabetic retinopathy, diabetic nephropathy, diabetic neuropathy), hyperinsulinemia, hyperlipidemia, dyslipidemia, atherosclerosis, hyperuricemia, gout, obesity (e.g., obesity due to metabolic syndrome), etc. Among these, the SGLT inhibitor of the present disclosure is suitable for the prevention or treatment of diabetes and diabetic complications, particularly type 2 diabetes.

[0037] The amount of the SGLT inhibitor of the present disclosure to be applied is not particularly limited, and an effective amount capable of inhibiting SGLT in vivo may be appropriately set depending on the formulation form, use, recipient, expected effect, etc. For example, when the SGLT inhibitor of the present disclosure is orally ingested or orally administered, the amount of intake or administration may be about 0.01 to 3,000 mg, preferably about 0.1 to 1,000 mg, of pectolinarigenin per day for an adult. The SGLT inhibitor of the present disclosure may be ingested or administered once or in several divided doses so that the daily amount falls within the above-mentioned range.

[0038] Each configuration and combination thereof in each embodiment is merely an example, and addition, omission, substitution, and other modifications of the configuration are possible as appropriate within the scope of the gist of this disclosure. Each aspect disclosed in this specification can be combined with any other feature disclosed in this specification. EXAMPLES

[0039] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the embodiments, but only by the scope of the claims.

[0040] Test Example 1: Evaluation of SGLT1 inhibitory activity of pectolinarigenin A test solution was prepared by adding 10 μM pectolinarigenin or 10 μM chlorogenic acid to a KRH (Krebs Ringer Hepes) buffer solution containing 2 mM 2DG (2-deoxyglucose).

[0041] Human SGLT1 highly expressing CHO cells (recombinant cells in which a human SGLT1 expression vector was introduced into CHO cells) were placed in each well of a 24-well plate at 2.0 × 10 5 The cells were seeded at 1000 cells / well and cultured overnight at 37°C. The culture supernatant of each well was then removed, and 0.5 ml of the test solution was added to each well and incubated at 37°C for 10 minutes. The cells in the wells were then collected and washed, and 0.1 M aqueous sodium hydroxide was added to dissolve the cells, which were then neutralized with 0.1 M hydrochloric acid. The amount of 2DG in the resulting cell lysate was measured using a Glucose Uptake-Glo Assay kit (Promega). In addition, a test solution containing no pectolinarigenin or chlorogenic acid was used as a control, and the same test was performed. The ratio of the amount of 2DG in the cell lysate in each test solution to the amount of 2DG in the cell lysate in the control was calculated and used as the 2DG uptake rate.

[0042] The results are shown in Figure 1. As a result, it was confirmed that pectolinarigenin was able to reduce the amount of 2DG uptake more than chlorogenic acid, which is known to have SGLT1 inhibitory activity, and has excellent SGLT1 inhibitory activity.

[0043] Test Example 2: Evaluation of the relationship between pectinarigenin concentration and SGLT1 inhibitory activity The 2DG uptake rate was determined in the same manner as in Test Example 1 above, using test solutions prepared by adding pectolinarigenin to 1.0, 2.5, 5.0, 10.0, and 25.0 μM in KRH (Krebs Ringer Hepes) buffer containing 2 mM 2DG.

[0044] The results are shown in Figure 2. As a result, it was confirmed that pectolinarigenin was able to reduce the amount of 2DG uptake in a concentration-dependent manner and was able to inhibit SGLT1 activity in a concentration-dependent manner.

[0045] Test Example 3: Evaluation of SGLT1 inhibitory activity of pectolinarigenin glycoside The 2DG uptake rate was determined in the same manner as in Test Example 1 above, using a test solution prepared by adding 5 μM pectolinarigenin or 5 μM pectolinarin to a KRH (Krebs Ringer Hepes) buffer solution containing 2 mM 2DG.

[0046] The results are shown in Figure 3. As a result, a decrease in the amount of 2DG uptake was observed in pectolinarin as well compared to the control, confirming that not only pectolinarigenin but also its glycosides have SGLT1 inhibitory activity.

Claims

1. A sodium-dependent glucose cotransporter inhibitor containing pectinarigenin and / or its glycoside as an active ingredient.

2. The sodium-dependent glucose cotransporter inhibitor according to claim 1 , which is used to inhibit sodium-dependent glucose cotransporter 1.

Citation Information

Patent Citations

  • Medicinal composition containing benzyl phenyl glucopyranoside derivative

    JP2011032174A

  • Preventing or therapeutic agent for diabetes, characterized by containing 4-isopropyl phenyl glucitol compound as active ingredient

    JP2012062308A

  • Pyrazole compound substituted with heteroaryl and pharmaceutical use thereof

    JP2019182852A

  • Adiponectin secretion promoting agent

    WO2020017568A1